Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

January 8, 2024

Study Completion Date

March 3, 2027

Conditions
Advanced Solid TumorMetastatic Solid TumorsMET Gene Alterations
Interventions
DRUG

elzovantinib (TPX-0022)

Oral elzovantinib (TPX-0022) capsules

Trial Locations (24)

22031

Local Institution - 2112, Fairfax

28036

Local Institution - 4104, Madrid

28040

Local Institution - 4103, Madrid

28050

Local Institution - 4101, Madrid

31008

Local Institution - 4102, Pamplona

38700

Local Institution - 4202, La Tronche

43614

Local Institution - 2104, Toledo

48109

Local Institution - 2106, Ann Arbor

48202

Local Institution - 2113, Detroit

60637

Local Institution - 2111, Chicago

63110

Local Institution - 2103, St Louis

69008

Local Institution - 4201, Lyon

80218

Local Institution - 2105, Denver

92093

Local Institution - 2102, La Jolla

92868

Local Institution - 2108, Orange

94160

Local Institution - 4203, Saint-Mandé

94805

Local Institution - 4204, Villejuif

02114

Local Institution - 2107, Boston

02215

Local Institution - 2109, Boston

77030-4009

Local Institution - 2101, Houston

05505

Local Institution - 6304, Seoul

06351

Local Institution - 6301, Seoul

03080

Local Institution - 6303, Seoul

120-752

Local Institution - 6302, Seoul

All Listed Sponsors
lead

Turning Point Therapeutics, Inc.

INDUSTRY